Association of <i>CYP2C19, CYP2D6</i> and <i>CYP3A4</i> Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients

Association of <i>CYP2C19, CYP2D6</i> and <i>CYP3A4</i> Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients

In the Amazon, the treatment for <i>Plasmodium vivax</i> is chloroquine plus primaquine. However, this regimen is limited due to the risk of acute hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Primaquine is a prodrug that requires conversion by the CYP2D6 enzyme to be...

Full description

Bibliographic Details
Main Authors: Marielle M. Macêdo, Anne C. G. Almeida, Gabrielly S. Silva, Amanda C. Oliveira, Victor I. Mwangi, Ana C. Shuan, Laila R. A. Barbosa, Fernanda Rodrigues-Soares, Gisely C. Melo
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Pathogens
Subjects:
<i>Plasmodium vivax</i>
malaria
primaquine hemolysis
G6PD deficiency
<i>CYP2C19</i>
<i>CYP2D6</i>
Online Access:https://www.mdpi.com/2076-0817/12/7/895

Internet

https://www.mdpi.com/2076-0817/12/7/895

Similar Items